

Melanoma UK

England & Wales - Charity number 1157635

Details

Other names	MELANOMA UK - INCORPORATING FACTOR 50, MELANOMA UK, FACTOR 50
Status	Registered
Legal form	Charitable company
Company number	08180701
Registered	2014-06-27
Register	View on the Charity Commission register

Contact

Address	Adamson House Towers Business Park Wilmslow Road Didsbury Manchester M20 2YY
Phone	0161 821 5657
Email	hello@melanomauk.org.uk
Website	www.melanomauk.org.uk

Activities

Objects: 1) TO PROMOTE HEALTH AND TO RELIEVE THOSE SUFFERING FROM OR AFFECTED BY MALIGNANT MELANOMA IN PARTICULAR BY:A) PROVIDING ADVICE AND GUIDANCE TO THOSE AFFECTED BY MALIGNANT MELANOMA AND UNBIASED AND ACCURATE INFORMATION ABOUT THE DISEASE TO THE WIDER PUBLIC;B) RAISING AWARENESS OF MALIGNANT MELANOMA AND ITS CAUSES AND SYMPTOMS;C) SUPPORTING RESEARCH INTO MALIGNANT MELANOMA AND ITS CURES, TREATMENTS AND PREVENTION2) TO ADVANCE THE EDUCATION OF THE GENERAL PUBLIC IN ALL AREAS RELATING TO MALIGNANT MELANOMA.

Activities: To provide support, education, and advocacy for the public in particular those impacted by Melanoma. We work in collaboration with skin professionals in the field of diagnosis, treatment, research and care. Our core focus is to help promote good skin health, reducing the instances and impact of this largely avoidable skin cancer by supporting advancements in prevention, treatment and cure.

Classification

- **How:** Sponsors Or Undertakes Research
- **What:** General Charitable Purposes, Education/training, The Advancement Of Health Or Saving Of Lives
- **Who:** Other Charities Or Voluntary Bodies, The General Public/mankind

Geography

- Throughout England

Finances

Period end	Income	Expenditure	Assets	Employees
2025-08-31	£211,758	£203,804	-	-
2024-08-31	£285,944	£241,113	-	-
2023-08-31	£455,227	£557,274	-	-
2022-08-31	£443,772	£388,416	-	-
2021-08-31	£265,268	£222,798	-	-

Trustees

Name	Role	Appointed
paula bridge	Chair	2014-02-24
Adrian Carroll		2015-11-05
Anita MILLER		2025-03-31
Barbara Cilindz		2025-06-17
DAVID BRIDGE		2014-02-24

Melanoma UK

England & Wales - Charity number 1157635

Accounts

Company registration number: 8180701

Charity registration number: 1157635

Melanoma UK Limited

(A company limited by guarantee)

Annual Report and Financial Statements

for the Year Ended 31 August 2025

Melanoma UK Limited

Contents

Reference and Administrative Details	1
Trustees' Report	2 to 9
Independent Examiner's Report	10
Statement of Financial Activities	11
Balance Sheet	12
Notes to the Financial Statements	13 to 21

Melanoma UK Limited

Reference and Administrative Details

Chief Executive Officer	Tracy Paine MBE (appointed 1 December 2024) Mark Rawden (ceased 31 October 2024)
Trustees	Paula Bridge (Chair) David Bridge Adrian Carroll Barbara Cilindz (appointed 17 June 202 Anita Christine Miller (appointed 31 March 2025)
Principal Office	Adamson House The Towers Business Park Didsbury Manchester M20 2YY
Registered Office	c/o Menzies LLP One Express 1 George Leigh Street Manchester M4 5DL
Company Registration Number	8180701
Charity Registration Number	1157635
Independent Examiner	Menzies LLP One Express 1 George Leigh Street Manchester M4 5DL

Melanoma UK Limited

Trustees' Report

The trustees present their annual report together with the financial statements of the Company for the year ended 31 August 2025. The annual report serves the purposes of both a Trustees' report and a directors' report under company law. The Trustees confirm that the annual report and financial statements of the charitable company comply with the current statutory requirements, the requirements of the charitable company's governing document and the provisions of the Statement of Recommended Practice (SORP) applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) (second edition of the Charities SORP (FRS102) October 2019, effective 1 J

Since the Company qualifies as small under section 382 of the Companies Act 2006, the Strategic Report required of medium and large companies under the Companies Act 2006 (Strategic Report and Directors' Report) Regulations 2013 has been omitted.

I am pleased to present the Chair's Report for 2025, a year in which Melanoma UK continued with its long-standing commitment to supporting communities across the UK through education, prevention and practical guidance on skin health. Throughout the year, the Charity has remained grounded in its founding values while adapting decisively to the changing needs of the public, clinicians, and partner organisations.

Our Mission

To provide support, education, and advocacy for individuals directly and indirectly impacted by melanoma, working in collaboration with clinical and research professionals. Our core focus is to promote skin health and reduce the incidence and impact of this avoidable cancer.

Our Vision

To make a difference in the fight against melanoma by supporting advancements in prevention, treatment, and cure. Through raising awareness and funds, we help individuals be proactive with early detection and ensure access to reliable information and guidance.

Public Benefit

The Trustees confirm they have complied with the duty in section 17 of the Charities Act 2011 to have due regard to the Charity Commission's guidance on public benefit.

The Board reaffirmed Melanoma UK's strategic commitment to prevention and public education, recognising the importance of reaching all age groups and communities with clear, accessible advice on UV protection and skin care. This year we strengthened our work in raising awareness through new campaigns, partnerships and digital engagement initiatives. With a continued rise in melanoma incidence, the Charity's role in promoting early detection and safe behaviours is more vital than ever.

We have also continued to differentiate our position within the wider melanoma landscape by maintaining a clear focus on prevention and public engagement, thereby complementing the work of other specialist organisations and charities.

Melanoma UK Limited

Trustees' Report

Objectives and activities

In setting objectives and planning for activities, the Trustees have given due consideration to general guidance published by the Charity Commission relating to public benefit, including the guidance 'Public benefit: running a charity (PB2)

Strategic Progress

The Charity has worked steadily toward the objectives set out in the Strategic Plan 2025–2028. These include increasing public awareness, advancing prevention messaging, strengthening educational resources and investing in research that can contribute to improved clinical outcomes.

This year reflects steady and positive progress across our five strategic objectives:

1. Raise funds to support the prevention, treatment, and cure of melanoma
2. Increase public awareness through education
3. Provide financial support for research and collaboration
4. Ensure accessible and reliable information
5. Advance advocacy and policy influence

The Board has monitored progress against these priorities throughout the year and is encouraged by the gains made in public visibility, clinical partnerships and the development of new tools and resources to support communities across the UK.

A notable milestone in 2025 has been the collaboration with Thiscovery to develop a national listening exercise for individuals with lived experience of melanoma and other skin cancers. This project is an important opportunity to shape Melanoma UK's future direction, ensuring our work remains grounded in the needs of those we serve.

Educational and Community engagement

Melanoma UK worked closely with clinical advisors, specialist nurses and ambassadors throughout the year, ensuring that our prevention messages aligned with best practice and reached the communities that need them most. Notable contributions included the expansion of our skin health FAQs, targeted education features developed with clinical experts, the continued development of training materials and skin-check awareness resources.

We also benefitted from the active engagement of our ambassadors who extended our reach through local events, media opportunities, and community-based projects. Their support remains vital, and we are grateful for their dedication. Some key activities in this year included the delivery of Skin protection Awareness sessions to groups including:

- Lupus Group (Cardiff)
- DHU Healthcare (planned for cancer awareness day)

Workplace wellness events were delivered at BAE Systems (at two UK manufacturing sites as well as an on-line session) and for Liz Earle colleagues based in John Lewis with excellent feedback.

Portland Clinical provided mole clinics on our behalf to colleagues at Watches of Switzerland (WOS) who also made a substantial donation to the Charity. WOS supported the Melanoma Garden at Manchester Flower Festival which provided strong public engagement across four days and featured on national TV and press.

Melanoma UK Limited

Trustees' Report

Review of activities

Governance and Organisational development

We were delighted to welcome Tracy Paine MBE to join the team as our new CEO in November 2024 . Tr has immense experience in the Charitable sector and is a valuable addition to t

The Board has maintained firm oversight of governance and compliance throughout the year. The ongoing Charity Commission inquiry has required detailed engagement, and the Charity has responded constructively and transparently to all requests for information. While this process has inevitably placed constraints on some external activities, it has also strengthened our internal systems, decision-making processes, and documentation standards.

- We continue to ensure that internal controls are robust, risks are monitored, and governance practices remain fit for purpose. The recruitment of additional trustees has broadened the Board's skills and strengthened financial and operational scrutiny.
- An HMRC Gift Aid audit was completed within required timescales.
- Trustees strengthened oversight with support from our newly appointed chartered finance professional.
- Operational effectiveness continued to improve under the leadership of the CEO and senior management team.
- The Board undertook a structured review of trustee tenure and skills requirements of maintaining strong leadership continuity as the Charity looks ahead to 2026 and beyond.

Melanoma UK Limited

Trustees' Report

Fundraising disclosures

Fundraising and Financial Stewardship

In 2025 we continued to take a careful, practical approach to income generation. We strengthened our relationships with corporate partners, expanded community fundraising initiatives and explored new grant opportunities, including the introduction of a structured application process with our medical advisors to ensure the grants process is fair and equitable.

Despite a challenging economic environment, the Charity remained financially stable, whilst making a material investment of funds, enabling us to continue delivering our mission.

Some of our key Corporate and Partnership Contributions have included:

- Watches of Switzerland: £25,00
- NYCDA Lottery: £13,003 YTD with ongoing weekly contributions
- Merck: £10,00
- Tennent's "Taps Off" Campaign: £6,000
- Jewson/Nivea Sun partnership: £6,000
- Vita Liberata (UV awareness campaign): £4,600
- Climbers Against Cancer
- RJC Plant Services 2025 Calendar : £8
- Dussl on-going partnership with donations from s

Community Fundraising Examples

- Kemsley Charitable Trust: £5,1
- Slinfold Golf Club COY: £3,800
- Performance Coaching toug
- GC Exercise fundraiser: £1,670
- Matt Bryant raffle: £1,062
- Tour de 4 ride :£9
- Miles for Melanoma: £627

In addition to this, there has been a steady stream of donations from smaller public fundraisers via Just In Memory Of and our own fundraising / appeal pages.

Charity Funds Expenditure

Key investments in 2025 were in line with our plans and Strategic Objectives such as funding research (see grants awarded below), raising awareness (such as the Manchester Flower festival public event) and public engagement (such as our National listening project). These projects alone represent circa £55,000 of actual and imminent spend with a further £30,000 to £50,000 spend in the pipeline for investment in diagnostic equipment currently being planned.

Research

Supporting meaningful research has remained a priority for the Charity. In 2025, two research grants were awarded following a robust, multidisciplinary assessment process. These grants support projects at the University of Birmingham and the University of Manchester each focused on critical areas of melanoma treatment science.

Melanoma UK Limited

Trustees' Report

Research Grants Awarded

1. University of Birmingham - Dr Matthew P

- Project: CMV-specific T-cells in melanoma to improve immune checkpoint therapy outcomes.
- Grant: £19,30
- Relationship strengthened through on-site visit and future collaboration potential. Lab visit took place in October 2025.

2. University of Manchester - Dr Rebeck

- Project: Understanding tumour microenvironment changes in liver metastases to optimise treatment.
- Grant: £9,995
- Laboratory visit took place in October 2025.

The Board recognises the importance of these investments, not only for their scientific value but also for the relationships they strengthen across clinical and academic sectors.

Financial review

The Charity's income is mainly from donations and discretionary sponsorship. Income for the year was £211,758 (2024: £285,944) with restricted income equating to £nil (2024 - £nil) and unrestricted to £211,758 (2024: 285,944).

At the end of the year there were total funds of £318,607 (2024: £310,653) comprising £4,562 (2024: £4,562) of restricted funds and £314,045 (2024: £306,091) of unrestricted funds.

Amounts held in fixed assets were £2,218 leaving £316,389 in free reserves.

Policy on reserves

The Trustees aim to maintain reserves in unrestricted funds at a desired level of £100,000, This level of reserves is considered to be reasonable to support the Charity's ongoing commitments.

At the financial year end, Melanoma UK's reserves were higher than the stated reserves policy of £100,000.

Plans for future periods

Aims and key objectives for future periods

Looking ahead

As we move into 2026, our priority remains clear: to protect and educate the public, support earlier detection and ensure individuals and families have access to reliable, practical information about melanoma and non-melanoma skin cancer. We will continue strengthening our governance, expanding our prevention work and developing the Charity's operational capacity.

The Trustees recognise the importance of building upon 2025's achievements with continued focus on:

- Strengthening financial sustainability
- Expanding evidence-based education
- Growing clinical partnerships
- Ensuring governance excellence
- Completing the national listening project and using its findings to inform 2026–2027 strategy
- Continuing to build influence in national policy on UV safety and skin cancer prevention

The Charity enters 2026 with strong foundations, renewed confidence across stakeholders, and a clear set of priorities.

The Trustees are responsible for preparing the Annual Report and Financial Statements in accordance with applicable law and UK accounting standards.

Melanoma UK Limited

Trustees' Report

Going concern

The Trustees have a reasonable expectation that the Charity has adequate resources to continue in operational existence for the foreseeable future.

Structure, governance and management

Melanoma UK is registered as a charitable company limited by guarantee and was set up by a Memorandum Association on 15/08/2012, and the Articles were since amended by a special resolution passed on 27/05/2014 with charity registration number 1157635.

Recruitment and appointment of trustees

The company is the responsibility of the trustees who are elected in accordance with the terms in its Memorandum of Association. The Trustees are legally responsible for managing, controlling, and directing the affairs of their charity. All directors of the company are also trustees of the Charity, and there are no other trustees. The trustees named below served in the year. The board has the power to appoint additional trustees as it considers fit to do so based on their suitability for the role. A board skills audit was undertaken with a view to expand the skillset of the board and recruitment is ongoing.

The Trustees who served during the year were: -

Mrs Paula Bridge (Chair)

Mr David Bridge

Mr Adrian Carroll

Mrs Barbara Cilindz (appointed 17 June 2025)

Mrs Anita Miller (appointed 31 March 2025)

Melanoma UK Limited

Trustees' Report

Organisational structure

Acknowledgements

On behalf of the Trustees, I extend sincere thanks to our CEO, Management and staff team, clinical adv ambassadors, supporters, and volunteers. Their dedication and professionalism underpin everything the Charity has achieved in 2025. We also thank our donors and fundraisers whose generosity enables us to pursue our mission. Their efforts, combined with careful financial management have ensured that Melanoma UK remains well positioned to deliver its charitable objectives.

Melanoma UK enters 2026 with a firm strategic direction and a strengthened foundation. The Board will continue to guide the Charity with diligence and commitment, ensuring we remain aligned with our core mission to reduce the incidence and impact of melanoma across the UK.

Raising Public Awareness and Education

We are consistently delivering three weekly social media posts with two dedicated to melanoma education and we have seen a significant increase in social media followers, impressions and engagement. Our commitment and has included high-profile media appearances in the national press and BBC radio stations. Also to note:

- Contribution to an RCN training video on performing mole checks with over 2,000 views in week one.
- Expansion of educational resources on the website including melanoma FAQs, non-melanoma skin cancer Q&A, child-friendly sun-safe posters and downloadable tools.
- Co-production of "Easy Read" leaflets for people with learning disabilities and autism.
- Co- production of RCN Nurse g
- Promotion and signposting of other accredited training for health and beauty and medical professionals

Partnerships and Sector Collaboration

Melanoma UK's relationship with clinicians, researchers and sector bodies remains central to our work. We have engaged constructively with organisations across dermatology, oncology, nursing and public health, ensuring our efforts align with emerging evidence and national priorities. We have put a great effort i signposting and support for SKcin's accredited MASCED Pro courses; promotion of Melanoma Fund and Melanoma Focus campaigns. We look forward to further collaboration in 2026.

Key Involvement

This year we have been committed to providing support for the national cancer initiatives to include;

- Oral and written evidence to the All-Party Parliamentary Group (APPG) on UV Safety and we have ongoin liaison with British Beauty Council
- Provided support for the Rare Cancer Bill through Cancer 52 collaborations.
- Participation in One Cancer Voice parliamentary stunt highlighting gaps in the National C
- Ongoing advocacy for banning commercial sunbeds in the UK in partnership with leading clinicians and academics.
- Contribution to national narrative following WHO recognition of SPF as an essential medicine.
- Clear and consistent signposting to reputable clinical and support servic
- Newsletter circulation surpassed 400 recipients with strong engagement.

Melanoma UK Limited

Trustees' Report

Statement of Trustees' Responsibilities

The trustees (who are also the directors of Melanoma UK Limited for the purposes of company responsible for preparing the trustees' report and the financial statements in accordance with the United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) and applicable law and regulations.

Company law requires the trustees to prepare financial statements for each financial year. Under company law the trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and apply them consistently;
- observe the methods and principles in the Charities SORP
- make judgements and estimates that are reasonable and prudent
- state whether applicable UK Accounting Standards have been followed, subject to any material departure disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charitable company's transactions and disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The annual report was approved by the trustees of the Charity on 03-Mar-2026 and signed on its behalf

Signed by:



.....F20753874AAF421w.....

Paula Bridge (Chair)
Trustee

Melanoma UK Limited

Independent Examiner's Report to the trustees of Melanoma UK Limited

I report on the accounts of the Charity for the year ended 31 August 2025 which are set out on pages 11 to 21 .

Respective responsibilities of trustees and examiner

The trustees (who are also the directors of the company for the purposes of company law) are responsible for the preparation of the accounts. The trustees consider that an audit is not required for this year under section 144(2) of the Charities Act 2011 (the 2011 Act) and that an independent examination is needed.

Having satisfied myself that the Charity is not subject to audit under company law and is eligible for independent examination, it is my responsibility to:

- examine the accounts under section 145 of the 2011 Act;
- to follow the procedures laid down in the general Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act; and
- to state whether particular matters have come to my attention.

Basis of independent examiner's report

My examination was carried out in accordance with the general Directions given by the Charity Commission. An examination includes a review of the accounting records kept by the Charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts, and seeking explanations from you as trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit and consequently no opinion is given as to whether the accounts present a 'true and fair view' and the report is limited to those matters set out in the statement below.

Independent examiner's statement

In connection with my examination, no matter has come to my attention:


(1) which gives me reasonable cause to believe that in any material respect the requirements:

- to keep accounting records in accordance with section 386 of the Companies Act 2006; and
- to prepare accounts which accord with the accounting records, comply with the accounting requirements of section 396 of the Companies Act 2006 and with the methods and principles of the Statement of Recommended Practice: Accounting and Reporting by Charities

have not been met; or

(2) to which, in my opinion, attention should be drawn in order to enable a proper understanding of the accounts to be reached.

Signed by:


.....
Helen Binns FRCR
ICAEW

One Express
1 George Leigh Street
Manchester
M4 5DL

03-Mar-2026

Date:.....

Melanoma UK Limited

Statement of Financial Activities for the Year Ended 31 August 2025 (Including Income and Expenditure Account and Statement of Total Recognised Gains and Losses)

	Note	Unrestricted funds £	Restricted funds £	Total 2025 £
Income and Endowments from:				
Donations and legacies	3	187,833	-	187,83
Other trading activities	4	17,861	-	17,86
Investment income	5	6,064	-	6,064
Total Income		<u>211,758</u>	<u>-</u>	<u>211,758</u>
Expenditure on:				
Charitable activities	6	203,804	-	203,804
Total Expenditure		<u>203,804</u>	<u>-</u>	<u>203,804</u>
Net income		<u>7,954</u>	<u>-</u>	<u>7,954</u>
Net movement in funds		7,954	-	7,954
Reconciliation of funds				
Total funds brought forward		<u>306,091</u>	<u>4,562</u>	<u>310,653</u>
Total funds carried forward	15	<u><u>314,045</u></u>	<u><u>4,562</u></u>	<u><u>318,607</u></u>
	Note	Unrestricted funds £	Restricted funds £	Total 2024 £
Income and Endowments from:				
Donations and legacies	3	267,102	-	267,1
Other trading activities	4	11,489	-	11,489
Investment income	5	7,353	-	7,353
Total Income		<u>285,944</u>	<u>-</u>	<u>285,944</u>
Expenditure on:				
Charitable activities	6	241,113	-	241,113
Total Expenditure		<u>241,113</u>	<u>-</u>	<u>241,113</u>
Net income		<u>44,831</u>	<u>-</u>	<u>44,831</u>
Net movement in funds		44,831	-	44,831
Reconciliation of funds				
Total funds brought forward		<u>261,260</u>	<u>4,562</u>	<u>265,822</u>
Total funds carried forward	15	<u><u>306,091</u></u>	<u><u>4,562</u></u>	<u><u>310,653</u></u>

All of the Charity's activities derive from continuing operations during the above two periods.
The funds breakdown for 2024 is shown in note 15.

Melanoma UK Limited
(Registration number: 8180701)
Balance Sheet as at 31 August 2025

	Note	2025 £	2024 £
Fixed assets			
Tangible assets	11	2,218	2,790
Current assets			
Stocks	12	13,374	8,985
Debtors	13	1,200	70,549
Cash at bank and in hand		<u>329,885</u>	<u>260,074</u>
		344,459	339,608
Creditors: Amounts falling due within one year	14	<u>(28,070)</u>	<u>(31,745)</u>
Net current assets		<u>316,389</u>	<u>307,863</u>
Net assets		<u>318,607</u>	<u>310,653</u>
Funds of the charity:			
Restricted funds		4,562	4,562
Unrestricted income funds			
Unrestricted funds		<u>314,045</u>	<u>306,091</u>
Total funds	15	<u>318,607</u>	<u>310,653</u>


For the financial year ending 31 August 2025 the Charity was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the Charity to obtain an audit of its accounts for the year in question in accordance with section 476; and
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements on pages 11 to 21 were approved by the trustees, and authorised for issue on 03-Mar-2026 and signed on their behalf by:

Signed by:

P20733874AAAF421
 Paula Bridge (Chair)
 Trustee

Melanoma UK Limited

Notes to the Financial Statements for the Year Ended 31 August 2025

1 Charity status

The Charity is a charity limited by guarantee and consequently does not have share capital. Each of the trust is liable to contribute an amount not exceeding £10 towards the assets of the Charity in the event of liquidation.

2 Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective from 1 January 2015) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

Basis of preparation

Melanoma UK Limited meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

Going concern

The trustees consider that there are no material uncertainties about the Charity's ability to continue as a going concern nor any significant areas of uncertainty that affect the carrying value of assets held by the Charity.

Exemption from preparing a cash flow statement

The Charity opted to early adopt Bulletin 1 published on 2 February 2016 and have therefore not included a cash flow statement in these financial statements.

Income and endowments

All income is recognised once the Charity has entitlement to the income, it is probable that the income will be received and the amount of the income receivable can be measured reliably.

Donations and legacies

Donations are recognised when the Charity has been notified in writing of both the amount and settlement date. In the event that a donation is subject to conditions that require a level of performance by the Charity before the Charity is entitled to the funds, the income is deferred and not recognised until either those conditions are fully met, or the fulfilment of those conditions is wholly within the control of the Charity and it is probable that these conditions will be fulfilled in the reporting period.

Melanoma UK Limited

Notes to the Financial Statements for the Year Ended 31 August 2025

Investment income

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Charity; this is normally upon notification of the interest paid or payable by the bank. Dividends are recognised once the dividend has been declared and notification has been received of the dividend due.

Expenditure

All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to that category. Where costs cannot be directly attributed to particular headings they have been allocated on a basis consistent with the use of resources, with central staff costs allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use. Other support costs are allocated based on the spread of staff costs.

Charitable activities

Charitable expenditure comprises those costs incurred by the Charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

Support costs

Support costs include central functions and have been allocated to activity cost categories on a basis consistent with the use of resources, for example, allocating property costs by floor areas, or per capita, staff costs by the time spent and other costs by their usage.

Governance costs

These include the costs attributable to the Charity's compliance with constitutional and statutory requirements, including audit, strategic management and trustees' meetings and reimbursed expenses.

Taxation

The Charity is considered to pass the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively to charitable purposes.

Tangible fixed assets

Individual fixed assets are initially recorded at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

Depreciation and amortisation

Depreciation is provided on tangible fixed assets so as to write off the cost or valuation, less any estimated residual value, over their expected useful economic life as follows:

Asset class	Depreciation method and rate
Motor vehicles	25% reducing balance
Fixtures, fittings and equipment	20% straight line
Office equipment	20% straight line

Melanoma UK Limited

Notes to the Financial Statements for the Year Ended 31 August 2025

Stock

Stock is valued at the lower of cost and estimated selling price less costs to complete and sell, after due regard for obsolete and slow moving stocks. Cost is determined using the first-in, first-out (FIFO).

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the Charity does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Fund structure

Unrestricted income funds are general funds that are available for use at the trustees's discretion in furtherance of the objectives of the Charity.

Designated funds are unrestricted funds earmarked by the trustees for particular future project or commitment.

Restricted income funds are those donated for use in a particular area or for specific purposes, the use of which is restricted to that area or purpose.

Financial instruments

Classification

Financial assets and financial liabilities are recognised when the Charity becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Charity after deducting all of its liabilities.

Melanoma UK Limited

Notes to the Financial Statements for the Year Ended 31 August 2025

Recognition and measurement

All financial assets and liabilities are initially measured at transaction price (including transaction costs), except for those financial assets classified as at fair value through profit or loss, which are initially measured at fair value (which is normally the transaction price excluding transaction costs), unless the arrangement constitutes a financing transaction. If an arrangement constitutes a financing transaction, the financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Financial assets and liabilities are only offset in the statement of financial position when, and only when there exists a legally enforceable right to set off the recognised amounts and the Charity intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Financial assets are derecognised when and only when a) the contractual rights to the cash flows from the financial asset expire or are settled, b) the Charity transfers to another party substantially all of the risks and rewards of ownership of the financial asset, or c) the Charity, despite having retained some, but not all, significant risks and rewards of ownership, has transferred control of the asset to another party.

Financial liabilities are derecognised only when the obligation specified in the contract is discharged, cancelled or expires.

3 Income from donations and legacies

	Unrestricted funds		
	General	Total	Total
	£	2025	2024
		£	£
Donations and legacies;			
Donations from individuals	181,674	181,674	256,690
Gift aid reclaimed	6,159	6,159	10,412
	<u>187,833</u>	<u>187,833</u>	<u>267,102</u>

4 Income from other trading activities

	Unrestricted funds		
	General	Total	Total
	£	2025	2024
		£	£
Lotteries and competitions income	17,861	17,861	11,489
	<u>17,861</u>	<u>17,861</u>	<u>11,489</u>

Melanoma UK Limited

Notes to the Financial Statements for the Year Ended 31 August 2025

5 Investment income

	Unrestricted funds	Total 2025	Total 2024
	General £	£	£
Interest receivable and similar income;			
Other interest receivable	6,064	6,064	7,353

6 Expenditure on charitable activities

		Unrestricted funds	Total 2025	Total 2024
	Note	General £	£	£
Staff costs	8	79,659	79,659	22,883
Allocated support costs		114,655	114,655	204,291
Governance costs	7	9,490	9,490	13,939
		<u>203,804</u>	<u>203,804</u>	<u>241,113</u>
		Activity support costs £	Total 2025 £	Total 2024 £
Fundraising costs		4,813	4,813	3,963
Advertising and marketing		13,552	13,552	9,019
Direct expenditure		38,593	38,593	(8,985)
Premises costs		131	131	1,808
Insurance		1,333	1,333	1,426
Finance costs		462	462	1,162
Motor and travel		2,067	2,067	2,173
Consulting		27,767	27,767	96,254
Entertainment		18	18	73
Staff costs		79,659	79,659	22,883
Staff training		580	580	-
Hire of equipment		-	-	457
Depreciation		652	652	2,698
Profit on disposal of fixed asset		-	-	(2,833)
Website and social media costs		16,104	16,104	16,328
Telephone and internet		4,141	4,141	7,305
Sundry		1,868	1,868	6,536
Legal and professional		1,176	1,176	2,173
Exceptional admin costs		-	-	62,638
Printing, postage and stationery		593	593	1,463
Office expenses		805	805	632

Melanoma UK Limited

Notes to the Financial Statements for the Year Ended 31 August 2025

	Activity support costs £	Total 2025 £	Total 2024 £
Governance	9,490	9,490	13,940
	<u>203,804</u>	<u>203,804</u>	<u>241,113</u>

£203,804 (2024 - £241,113) of the above expenditure was attributable to unrestricted funds and £Nil (2024 - £Nil) to restricted funds.

7 Analysis of governance and support costs

Governance costs

	Unrestricted funds General £	Total 2025 £	Total 2024 £
Independent examiner fees			
Examination of the financial statements	3,300	3,300	3,300
Other fees paid to examiners	6,190	6,190	10,639
	<u>9,490</u>	<u>9,490</u>	<u>13,939</u>

8 Staff costs

The aggregate payroll costs were as follows:

	2025 £	2024 £
Staff costs during the year were:		
Wages and salaries	78,333	22,508
Pension costs	1,326	375
	<u>79,659</u>	<u>22,883</u>

The monthly average number of persons (including senior management team) employed by the Charity during the year expressed as full time equivalents was as follows:

	2025 No	2024 No
Average number of employees including directors	<u>7</u>	<u>4</u>

The total employee benefits of the key management personnel of the Charity were £Nil (2024 - £Ni

Melanoma UK Limited

Notes to the Financial Statements for the Year Ended 31 August 2025

9 Independent examiner's remuneration

	2025 £	2024 £
Examination of the financial statements	3,300	3,300
Other fees to examiners		
All other services	6,190	10,639

10 Taxation

The Charity is a registered charity and is exempt from taxation of its income and gains falling within section 524 of the Income Tax Act 2007 to the extent that they are applied to its charitable objectives. No tax charge has arisen in the current and prior year.

11 Tangible fixed assets

	Furniture and equipment £	Total £
Cost		
At 1 September	3,170	3,170
Additions	80	80
At 31 August 2025	3,250	3,250
Depreciation		
At 1 September 202	380	380
Charge for the year	652	652
At 31 August 2025	1,032	1,032
Net book value		
At 31 August 2025	2,218	2,218
At 31 August 2024	2,790	2,790

12 Stock

	2025 £	2024 £
Stocks	13,374	8,985

13 Debtors

	2025 £	2024 £
Accrued income	1,200	70,549

Melanoma UK Limited

Notes to the Financial Statements for the Year Ended 31 August 2025

14 Creditors: amounts falling due within one year

	2025 £	2024 £
Trade creditors	21,999	25,752
Other taxation and social security	274	(947)
Other creditors	307	-
Accruals	5,490	6,940
	<u>28,070</u>	<u>31,745</u>

15 Funds

	Balance at 1 September 2024 £	Incoming resources £	Resources expended £	Balance at 31 August 2025 £
Unrestricted funds				
<i>General</i>				
General	306,091	211,758	(203,804)	314,045
Restricted funds				
Non Melanoma Skin Cancer	1,000	-	-	1,000
B-raf Awareness	3,562	-	-	3,562
Total restricted funds	<u>4,562</u>	<u>-</u>	<u>-</u>	<u>4,562</u>
Total funds	<u>310,653</u>	<u>211,758</u>	<u>(203,804)</u>	<u>318,607</u>
	Balance at 1 September 2023 £	Incoming resources £	Resources expended £	Balance at 31 August 2024 £
Unrestricted funds				
<i>General</i>				
General	261,260	285,944	(241,113)	306,091
Restricted funds				
Non Melanoma Skin Cancer	1,000	-	-	1,000
B-raf Awareness	3,562	-	-	3,562
Total restricted funds	<u>4,562</u>	<u>-</u>	<u>-</u>	<u>4,562</u>
Total funds	<u>265,822</u>	<u>285,944</u>	<u>(241,113)</u>	<u>310,653</u>

Melanoma UK Limited

Notes to the Financial Statements for the Year Ended 31 August 2025

16 Analysis of net assets between funds

	Unrestricted funds	Restricted funds	Total funds
	General £	£	£
Tangible fixed assets	2,218	-	2,21
Current assets	339,897	4,562	344,459
Current liabilities	(28,070)	-	(28,070)
Total net assets	314,045	4,562	318,607

Melanoma UK

England & Wales - Charity number 1157635

Accounts

Company registration number: 8180701

Charity registration number: 1157635

Melanoma UK Limited

(A company limited by guarantee)

Annual Report and Financial Statements

for the Year Ended 31 August 2024

Beever and Struthers
One Express
1 George Leigh Street
Manchester
M4 5DL

Melanoma UK Limited

Contents

Reference and Administrative Details	1
Trustees' Report	2 to 6
Independent Examiner's Report	7
Statement of Financial Activities	8
Balance Sheet	9
Notes to the Financial Statements	10 to 20

Melanoma UK Limited

Reference and Administrative Details

Chief Executive Officer	Mark Rawden (ceased 31 October 2024)
Trustees	David Bridge Adrian Carroll Paula Bridge
Principal Office	Adamson House The Towers Business Park Didsbury Manchester M20 2YY
Registered Office	C/o Beever and Struthers One Express 1 George Leigh Street Manchester M4 5DL
Company Registration Number	8180701
Charity Registration Number	1157635
Independent Examiner	Beever and Struthers One Express 1 George Leigh Street Manchester M4 5DL

Melanoma UK Limited

Trustees' Report

The trustees present their annual report together with the financial statements of the Company for the year ended 31 August 2024. The annual report serves the purposes of both a Trustees' report and a directors' report under company law. The Trustees confirm that the annual report and financial statements of the charitable company comply with the current statutory requirements, the requirements of the charitable company's governing document and the provisions of the Statement of Recommended Practice (SORP) applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) (second edition of the Charities SORP (FRS102) October 2019, effective 1 January 2019).

Since the Company qualifies as small under section 382 of the Companies Act 2006, the Strategic Report required of medium and large companies under the Companies Act 2006 (Strategic Report and Directors' Report) Regulations 2013 has been omitted.

Objectives and activities

In setting objectives and planning for activities, the Trustees have given due consideration to general guidance published by the Charity Commission relating to public benefit, including the guidance 'Public benefit: running a charity (PB2)'.

The objects of Melanoma UK Incorporating Factor 50 (hereinafter referred to as Melanoma UK) as set out in its Memorandum of Association are to:

1. To provide patient support and assist in the awareness of the condition Malignant Melanoma.
2. To provide funds for vital research with regards to the development of drugs to prolong and preserve quality of life.
3. To educate and increase awareness of the dangers of Melanoma.

We have developed 2 vision/mission statements to help us remain focused within our activities.

Our Vision is to make a difference in the fight against melanoma by supporting advancements in prevention, treatment, and cure. By raising funds and awareness, we will help individuals to be proactive with early detection and provide information about diagnosis, treatment and support through their journey with Melanoma

Our Mission is to provide support, education, and advocacy for those directly and indirectly impacted by Melanoma, in collaboration and alignment with professionals working in the field of diagnosis, treatment and research. Our core focus is to help promote skin health by reducing the instances and impact of this largely avoidable skin cancer.

Strategic Objectives

1. Raise funds to support the prevention, treatment and cure of Melanoma
2. Increase public awareness through education about Melanoma.
3. Provide financial support for research and collaboration
4. Ensure accessible reliable information for individuals affected by Melanoma
5. Advocacy and policy influence:

Melanoma UK Limited

Trustees' Report

Review of activities

From a modest level of fundraising activity at the end of 2023 we have worked hard to increase levels throughout 2024 and into 2025.

We had our very successful Beauty Spotters campaign which was launched in May 2024 where we focused on the beauty industry highlighting the risks of Acral melanoma within the Black and Brown communities. This got a lot of exposure from the main tabloids and magazines such as Cosmopolitan and Women's Health

This was closely followed by the "1804 Garden", the headlining show garden, which featured at RHS Tatton Garden show in July 2024 . The design by Carolyn Harden and Jon Jarvis won a silver award at the show for its intuitive design highlighting skin cancer and the link between physical and mental health. The Melanoma team were on hand every day to engage with the public offering advice on safe sun.

After Tatton a scaled down version was on show at the Southport flower show before being finally donated to Lancashire and South Cumbria NHS Foundation Trust to be used as a well being garden for mental health patients and NHS workers.

On the back of last years very successful awareness campaigns we have continued our partnership with Jewson Builder's merchants, one of the largest builders merchants in the UK. We were invited to attend and provide speakers for numerous live events across the country.

We are delighted to confirm that we been able to place another Horus 800 mole mapping machine this time within the Norfolk and Norwich University Hospital which will enable them to supply to patients across the region and will help identify issues earlier and receive treatment sooner which will ultimately save lives. The machine was donated in memory of Neil Evans by the funds raised by his family and friends and we were delighted to meet his family for the unveiling of the plaque recognizing the donation in Neil's memory.

We were delighted to see our Ambassador David Utterly scale the heights of Kilimanjaro for a second time in aid of Melanoma UK. David's support with fundraising , giving talks and appearing on radio interviews has been amazing over the last year and is greatly appreciated by all.

We have worked closely with the team at Run for Charity and on the back of receiving more applications to support Melanoma UK have secured 5 places for the London Landmarks , 15 runners for the Hackney Half marathon and we are delighted to have secured a place in the London Marathon for 2025

The Charity's lottery was relaunched as the "1804" (recognizing the year Melanoma was first mentioned in medical journals) and our general appeal for use of funds wherever the need is greatest along with individual fundraiser activity have positively impacted the charity funds.

Improved awareness is being pushed on several fronts via Website & SM activity, partnerships, connections with professional organisations, clinicians and now recently government (via MUK presence at a parliamentary round table in March which is expected to develop further). There has been some good work on education/ awareness materials and increased connections with other Charities.

Recently MUK joined One Cancer Voice via Cancer 52, calling on the UK government for more investment to fully fund the national Cancer Plan. This was shared across media.

Another positive development on this objective is recent invite and attendance of a Parliamentary roundtable on UV safety linked to Sunbeds. This is expected to develop into a joint campaign including respected representatives from across the Beauty industry and media. The potential outcomes of this could lead to better awareness and hopefully control and legislation (including Gov Health warnings at point of use).

Melanoma UK Limited

Trustees' Report

Financial review

The charity's income is mainly from donations and discretionary sponsorship. Income for the year was £285,944 (2023: £455,227) with restricted income equating to £nil (2023 - £nil) and unrestricted to £285,944 (2023: £455,227).

At the end of the year there were total funds of £310,653 (2023: £265,822) comprising £4,562 (2023: £4,562) of restricted funds and £306,091 (2023: £261,260) of unrestricted funds.

Amounts held in fixed assets were £2,790 leaving £307,863 in free reserves.

Despite the difficulties experienced by the impact of Covid -19 and the current Public enquiry the Trustees have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future and are optimistic about its position going forward having secured new partnerships which will benefit the charity going forward.

We have improved control on spend with updated financial policies and tighter expenses management, unrequired services have been terminated and settlement of outstanding/ disputed charges have helped rationalize the accounting process leading to lower financial accounting and legal costs moving forward. Quarterly Financial updates are in place with our external accountants, including financial outlook benchmarking.

MUK has made solid progress across its strategic objectives, particularly in partnerships, fundraising structure, public awareness, and advocacy. Continued focus on corporate engagement, structured fundraising, and policy influence will be key to maintaining momentum.

With the evolution, stabilisation and development of the Charity, MUK is becoming better placed to engage with external organisations and progress is being made in this area. Connections with NHS parties, Cancer 52 and others have been remade and confidence is growing. With a larger, increasingly diverse and experienced Trustee team, coupled with renewed senior management and CEO leadership, MUK is becoming better placed to have a 'voice at the table' in Melanoma related matters.

Policy on reserves

The Trustees aim to maintain reserves in unrestricted funds at a desired level of £100,000, This level of reserves is considered to be reasonable to support the charity's ongoing commitments.

At the financial year end, Melanoma UK's reserves were higher than the stated reserves policy of £100,000.

Plans for future periods

Aims and key objectives for future periods

The current Trustees intend to expand the board of Trustees to add specific skill sets, to increase Trustee involvement and supervision who will compliment the scheme of delegation which has been devised. The fundamentals of the Charity will be maintained and strengthened. The Charity will continue to reduced expense levels by moving to a virtual platform following the closure of the physical office which will enable it to devote more time and funds to the charitable aims. The charity has a wealth of support and a genuine reason to thrive.

Going concern

The Trustees have a reasonable expectation that the Charity has adequate resources to continue in operational existence for the foreseeable future.

Melanoma UK Limited

Trustees' Report

Structure, governance and management

Melanoma UK is registered as a charitable company limited by guarantee and was set up by a Memorandum of Association on 15/08/2012, and the Articles were since amended by a special resolution passed on 27/05/2014 with charity registration number 1157635.

Recruitment and appointment of trustees

The company is the responsibility of the trustees who are elected in accordance with the terms in its Memorandum of Association. The Trustees are legally responsible for managing, controlling, and directing the affairs of their charity. All directors of the company are also trustees of the charity, and there are no other trustees. The trustees named below served in the year. The board has the power to appoint additional trustees as it considers fit to do so based on their suitability for the role. A board skills audit was undertaken with a view to expand the skillset of the board and recruitment is ongoing.

The Trustees who served during the year were: -

Mrs Paula Bridge
Mr David Bridge
Mr Adrian Carroll

Organisational structure

People support has improved with the full time Administration role ensuring timely responses to enquiries (including signposting) as well as consistent support and thank you communications for donations and fundraisers. Lindsey Brough is assisted by Deborah Thomassen who continues in a part-time capacity to lend support and HR guidance.

We bid farewell to our interim CEO Mark Rawden and welcomed our new permanent CEO Tracy Paine MBE who has a wealth of experience in the charity sector. She is ably assisted in the management of the Charity by Colin Glover our COO who has had a huge impact on the internal functions and governance within the Charity.

Melanoma UK Limited

Trustees' Report

Statement of Trustees' Responsibilities

The trustees (who are also the directors of Melanoma UK Limited for the purposes of company law) are responsible for preparing the trustees' report and the financial statements in accordance with the United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) and applicable law and regulations.

Company law requires the trustees to prepare financial statements for each financial year. Under company law the trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charitable company's transactions and disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The annual report was approved by the trustees of the charity on17/04/25..... and signed on its behalf by:

David Bridge
.....

David Bridge
Trustee

Melanoma UK Limited

Independent Examiner's Report to the trustees of Melanoma UK Limited

I report on the accounts of the charity for the year ended 31 August 2024 which are set out on pages 8 to 20 .

Respective responsibilities of trustees and examiner

The trustees (who are also the directors of the company for the purposes of company law) are responsible for the preparation of the accounts. The trustees consider that an audit is not required for this year under section 144(2) of the Charities Act 2011 (the 2011 Act) and that an independent examination is needed. The charity's gross income exceeded £250,000 and I am qualified to undertake the examination by being a qualified member of ICAEW .

Having satisfied myself that the charity is not subject to audit under company law and is eligible for independent examination, it is my responsibility to:

- examine the accounts under section 145 of the 2011 Act;
- to follow the procedures laid down in the general Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act; and
- to state whether particular matters have come to my attention.

Basis of independent examiner's report

My examination was carried out in accordance with the general Directions given by the Charity Commission. An examination includes a review of the accounting records kept by the charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts, and seeking explanations from you as trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit and consequently no opinion is given as to whether the accounts present a 'true and fair view' and the report is limited to those matters set out in the statement below.

Independent examiner's statement

In connection with my examination, no matter has come to my attention:

(1) which gives me reasonable cause to believe that in any material respect the requirements:

- to keep accounting records in accordance with section 386 of the Companies Act 2006; and
- to prepare accounts which accord with the accounting records, comply with the accounting requirements of section 396 of the Companies Act 2006 and with the methods and principles of the Statement of Recommended Practice: Accounting and Reporting by Charities

have not been met; or

(2) to which, in my opinion, attention should be drawn in order to enable a proper understanding of the accounts to be reached.



.....
Helen Binns FCA
ICAEW

One Express
1 George Leigh Street
Manchester
M4 5DL

Date: 17 April 2025.....

Melanoma UK Limited

Statement of Financial Activities for the Year Ended 31 August 2024 (Including Income and Expenditure Account and Statement of Total Recognised Gains and Losses)

	Note	Unrestricted funds £	Restricted funds £	Total 2024 £
Income and Endowments from:				
Donations and legacies	3	267,102	-	267,102
Other trading activities	4	11,489	-	11,489
Investment income	5	7,353	-	7,353
Total Income		285,944	-	285,944
Expenditure on:				
Charitable activities	6	241,113	-	241,113
Total Expenditure		241,113	-	241,113
Net income		44,831	-	44,831
Net movement in funds		44,831	-	44,831
Reconciliation of funds				
Total funds brought forward		261,260	4,562	265,822
Total funds carried forward	16	306,091	4,562	310,653
	Note	Unrestricted funds £	Restricted funds £	Total 2023 £
Income and Endowments from:				
Donations and legacies	3	418,837	-	418,837
Other trading activities	4	30,661	-	30,661
Investment income	5	5,729	-	5,729
Total Income		455,227	-	455,227
Expenditure on:				
Charitable activities	6	557,274	-	557,274
Total Expenditure		557,274	-	557,274
Net expenditure		(102,047)	-	(102,047)
Transfers between funds		40,050	(40,050)	-
Net movement in funds		(61,997)	(40,050)	(102,047)
Reconciliation of funds				
Total funds brought forward		323,257	44,612	367,869
Total funds carried forward	16	261,260	4,562	265,822

All of the charity's activities derive from continuing operations during the above two periods.

The funds breakdown for 2023 is shown in note 16.

Melanoma UK Limited
(Registration number: 8180701)
Balance Sheet as at 31 August 2024

	Note	2024 £	2023 £
Fixed assets			
Tangible assets	12	2,790	29,865
Current assets			
Stocks	13	8,985	-
Debtors	14	70,549	77,746
Cash at bank and in hand		260,074	426,558
		339,608	504,304
Creditors: Amounts falling due within one year	15	(31,745)	(268,347)
Net current assets		307,863	235,957
Net assets		310,653	265,822
Funds of the charity:			
Restricted funds		4,562	4,562
Unrestricted income funds			
Unrestricted funds		306,091	261,260
Total funds	16	310,653	265,822

For the financial year ending 31 August 2024 the charity was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the charity to obtain an audit of its accounts for the year in question in accordance with section 476; and
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements on pages 8 to 20 were approved by the trustees, and authorised for issue on ~~17.04.25~~ and signed on their behalf by:

David Bridge

 David Bridge
 Trustee

Melanoma UK Limited

Notes to the Financial Statements for the Year Ended 31 August 2024

1 Charity status

The charity is a charity limited by guarantee and consequently does not have share capital. Each of the trustees is liable to contribute an amount not exceeding £10 towards the assets of the charity in the event of liquidation.

2 Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

Basis of preparation

Melanoma UK Limited meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

Going concern

The trustees consider that there are no material uncertainties about the charity's ability to continue as a going concern nor any significant areas of uncertainty that affect the carrying value of assets held by the charity.

Exemption from preparing a cash flow statement

The charity opted to early adopt Bulletin 1 published on 2 February 2016 and have therefore not included a cash flow statement in these financial statements.

Income and endowments

All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of the income receivable can be measured reliably.

Donations and legacies

Donations are recognised when the charity has been notified in writing of both the amount and settlement date. In the event that a donation is subject to conditions that require a level of performance by the charity before the charity is entitled to the funds, the income is deferred and not recognised until either those conditions are fully met, or the fulfilment of those conditions is wholly within the control of the charity and it is probable that these conditions will be fulfilled in the reporting period.

Melanoma UK Limited

Notes to the Financial Statements for the Year Ended 31 August 2024

Investment income

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the bank. Dividends are recognised once the dividend has been declared and notification has been received of the dividend due.

Expenditure

All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to that category. Where costs cannot be directly attributed to particular headings they have been allocated on a basis consistent with the use of resources, with central staff costs allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use. Other support costs are allocated based on the spread of staff costs.

Charitable activities

Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

Support costs

Support costs include central functions and have been allocated to activity cost categories on a basis consistent with the use of resources, for example, allocating property costs by floor areas, or per capita, staff costs by the time spent and other costs by their usage.

Governance costs

These include the costs attributable to the charity's compliance with constitutional and statutory requirements, including audit, strategic management and trustees' meetings and reimbursed expenses.

Taxation

The charity is considered to pass the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively to charitable purposes.

Tangible fixed assets

Individual fixed assets are initially recorded at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

Depreciation and amortisation

Depreciation is provided on tangible fixed assets so as to write off the cost or valuation, less any estimated residual value, over their expected useful economic life as follows:

Asset class	Depreciation method and rate
Motor vehicles	25% reducing balance
Fixtures, fittings and equipment	20% straight line
Office equipment	20% straight line

Melanoma UK Limited

Notes to the Financial Statements for the Year Ended 31 August 2024

Stock

Stock is valued at the lower of cost and estimated selling price less costs to complete and sell, after due regard for obsolete and slow moving stocks. Cost is determined using the first-in, first-out (FIFO).

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the charity does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Fund structure

Unrestricted income funds are general funds that are available for use at the trustees's discretion in furtherance of the objectives of the charity.

Designated funds are unrestricted funds earmarked by the trustees for particular future project or commitment.

Restricted income funds are those donated for use in a particular area or for specific purposes, the use of which is restricted to that area or purpose.

Financial instruments

Classification

Financial assets and financial liabilities are recognised when the charity becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the charity after deducting all of its liabilities.

Melanoma UK Limited

Notes to the Financial Statements for the Year Ended 31 August 2024

Recognition and measurement

All financial assets and liabilities are initially measured at transaction price (including transaction costs), except for those financial assets classified as at fair value through profit or loss, which are initially measured at fair value (which is normally the transaction price excluding transaction costs), unless the arrangement constitutes a financing transaction. If an arrangement constitutes a financing transaction, the financial asset or financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Financial assets and liabilities are only offset in the statement of financial position when, and only when there exists a legally enforceable right to set off the recognised amounts and the charity intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Financial assets are derecognised when and only when a) the contractual rights to the cash flows from the financial asset expire or are settled, b) the charity transfers to another party substantially all of the risks and rewards of ownership of the financial asset, or c) the charity, despite having retained some, but not all, significant risks and rewards of ownership, has transferred control of the asset to another party.

Financial liabilities are derecognised only when the obligation specified in the contract is discharged, cancelled or expires.

3 Income from donations and legacies

	Unrestricted funds		
	General	Total	Total
	£	2024	2023
		£	£
Donations and legacies;			
Donations from individuals	256,690	256,690	358,700
Gift aid reclaimed	10,412	10,412	60,137
	<u>267,102</u>	<u>267,102</u>	<u>418,837</u>

4 Income from other trading activities

	Unrestricted funds		
	General	Total	Total
	£	2024	2023
		£	£
Trading income;			
Shop income from sale of donated goods and services	-	-	11,208
Lotteries and competitions income	11,489	11,489	19,453
	<u>11,489</u>	<u>11,489</u>	<u>30,661</u>

Melanoma UK Limited

Notes to the Financial Statements for the Year Ended 31 August 2024

5 Investment income

	Unrestricted funds		
	General	Total	Total
	£	2024	2023
		£	£
Interest receivable and similar income;			
Other interest receivable	<u>7,353</u>	<u>7,353</u>	<u>5,729</u>

Melanoma UK Limited

Notes to the Financial Statements for the Year Ended 31 August 2024

6 Expenditure on charitable activities

		Unrestricted funds		
	Note	General £	Total 2024 £	Total 2023 £
Staff costs	9	22,882	22,882	143,597
Allocated support costs		204,291	204,291	408,943
Governance costs	7	13,940	13,940	4,734
		<u>241,113</u>	<u>241,113</u>	<u>557,274</u>
		Activity support costs £	Total 2024 £	Total 2023 £
Fundraising costs		3,963	3,963	13,315
Advertising and marketing		9,019	9,019	8,219
Direct expenditure		(8,985)	(8,985)	14,118
Premises costs		1,808	1,808	13,265
Insurance		1,426	1,426	1,693
Finance costs		1,162	1,162	1,336
Motor and travel		2,173	2,173	3,443
Consulting		96,254	96,254	36,954
Entertainment		73	73	-
Staff costs		22,883	22,883	143,597
Staff training		-	-	3,500
Hire of equipment		457	457	658
Depreciation		2,698	2,698	9,955
Profit on disposal of fixed asset		(2,833)	(2,833)	-
Website and social media costs		16,328	16,328	12,897
Telephone and internet		7,305	7,305	6,008
Sundry		6,536	6,536	1,938
Interest payable		-	-	3,163
Event costs		-	-	33,000
Provision of medical equipment		-	-	118,233
Legal and professional		2,173	2,173	30,312
Exceptional admin costs		62,638	62,638	96,936
Printing, postage and stationery		1,463	1,463	-
Office expenses		632	632	-
Governance		13,940	13,940	4,734
		<u>241,113</u>	<u>241,113</u>	<u>557,274</u>

£241,113 (2023 - £557,274) of the above expenditure was attributable to unrestricted funds and £Nil (2023 - £Nil) to restricted funds.

Melanoma UK Limited

Notes to the Financial Statements for the Year Ended 31 August 2024

7 Analysis of governance and support costs

Governance costs

	Unrestricted funds		
	General	Total	Total
	£	2024	2023
		£	£
Independent examiner fees			
Examination of the financial statements	3,300	3,300	3,300
Other fees paid to examiners	10,640	10,640	1,434
	<u>13,940</u>	<u>13,940</u>	<u>4,734</u>

8 Trustees remuneration and expenses

During the year the charity made the following transactions with trustees:

Gillian Nuttall

Gillian Nuttall received remuneration of £8,370 (2023: £68,480) during the year.

At the year end there was an amount due from Gillian Nuttall, a former trustee, of £17,776 (2023: £17,610). As this is unlikely to be recoverable, for accounting purposes this amount has been written off to exceptional administration expenses.

9 Staff costs

The aggregate payroll costs were as follows:

	2024	2023
	£	£
Staff costs during the year were:		
Wages and salaries	22,508	103,665
Social security costs	-	36,201
Pension costs	374	1,931
Other staff costs	-	1,800
	<u>22,882</u>	<u>143,597</u>

The monthly average number of persons (including senior management team) employed by the charity during the year expressed as full time equivalents was as follows:

	2024	2023
	No	No
Average number of employees including directors	<u>-</u>	<u>6</u>

The number of employees whose emoluments fell within the following bands was:

Melanoma UK Limited

Notes to the Financial Statements for the Year Ended 31 August 2024

	2023
	No
£60,001 - £70,000	<u>1</u>

The total employee benefits of the key management personnel of the charity were £Nil (2023 - £12,650).

10 Independent examiner's remuneration

	2024	2023
	£	£
Examination of the financial statements	<u>3,300</u>	<u>3,300</u>
Other fees to examiners		
All other services	<u>10,640</u>	<u>1,434</u>

Melanoma UK Limited

Notes to the Financial Statements for the Year Ended 31 August 2024

11 Taxation

The charity is a registered charity and is exempt from taxation of its income and gains falling within section 524 of the Income Tax Act 2007 to the extent that they are applied to its charitable objectives. No tax charge has arisen in the current and prior year.

12 Tangible fixed assets

	Furniture and equipment £	Motor vehicles £	Total £
Cost			
At 1 September 2023	6,268	52,688	58,956
Additions	2,790	-	2,790
Disposals	(5,888)	(52,688)	(58,576)
At 31 August 2024	<u>3,170</u>	<u>-</u>	<u>3,170</u>
Depreciation			
At 1 September 2023	6,040	23,051	29,091
Charge for the year	228	2,470	2,698
Eliminated on disposals	(5,888)	(25,521)	(31,409)
At 31 August 2024	<u>380</u>	<u>-</u>	<u>380</u>
Net book value			
At 31 August 2024	<u>2,790</u>	<u>-</u>	<u>2,790</u>
At 31 August 2023	<u>228</u>	<u>29,637</u>	<u>29,865</u>

13 Stock

	2024
	£
Stocks	<u>8,985</u>

14 Debtors

	2024	2023
	£	£
Accrued income	70,549	60,137
Other debtors	-	17,609
	<u>70,549</u>	<u>77,746</u>

Melanoma UK Limited

Notes to the Financial Statements for the Year Ended 31 August 2024

15 Creditors: amounts falling due within one year

	2024 £	(As restated) 2023 £
Trade creditors	25,752	74,243
Other taxation and social security	(947)	82,341
Other creditors	-	4,393
Accruals	6,940	107,370
	31,745	268,347

16 Funds

	Balance at 1 September 2023 £	Incoming resources £	Resources expended £	Balance at 31 August 2024 £
Unrestricted funds				
<i>General</i>				
General	261,260	285,944	(241,113)	306,091
Restricted funds				
Non Melanoma Skin Cancer	1,000	-	-	1,000
B-raf Awareness	3,562	-	-	3,562
Total restricted funds	4,562	-	-	4,562
Total funds	265,822	285,944	(241,113)	310,653

	Balance at 1 September 2022 £	Incoming resources £	Resources expended £	Transfers £	Balance at 31 August 2023 £
Unrestricted funds					
<i>General</i>					
General	323,257	455,227	(557,274)	40,050	261,260
Restricted funds					
Mole Hunt	40,050	-	-	(40,050)	-
Non Melanoma Skin Cancer	1,000	-	-	-	1,000
B-raf Awareness	3,562	-	-	-	3,562
Total restricted funds	44,612	-	-	(40,050)	4,562
Total funds	367,869	455,227	(557,274)	-	265,822

Melanoma UK Limited

Notes to the Financial Statements for the Year Ended 31 August 2024

17 Analysis of net assets between funds

	Unrestricted funds	Restricted funds	Total funds
	General £	£	£
Tangible fixed assets	2,790	-	2,790
Current assets	324,634	4,562	329,196
Current liabilities	(31,745)	-	(31,745)
Total net assets	<u>295,679</u>	<u>4,562</u>	<u>300,241</u>

Melanoma UK

England & Wales - Charity number 1157635

Accounts

MELANOMA UK INCORPORATING FACTOR 50

(Limited by guarantee)

Financial Statements

For the Year ended 31 August 2021

Company Number 08180701 (England and Wales)

Charity number 1157635

MELANOMA UK INCORPORATING FACTOR 50

Page 2

COMPANY LIMITED BY GUARANTEE

COMPANY NUMBER 08180701

CHARITY NUMBER 1157635

YEAR ENDED 31 AUGUST 2021

Contents

	<u>Page</u>
Charity Information	3
Report of the Directors/Trustees	4-5
Independent Examiner's Report	6
Statement of Financial Activities	7
Balance Sheet	8
Notes forming part of the financial statements	9-11

COMPANY LIMITED BY GUARANTEE

COMPANY NUMBER 08180701

CHARITY NUMBER 1157635

YEAR ENDED 31 AUGUST 2021

Charity Information

Board of Trustees & Directors

Mr Adrian Carroll
Mrs Paula Bridge
Mr David Bridge
Mrs Gillian Nuttall

Registered office

31 Market Street
Shaw
Oldham
OL2 8NR

Charity Number

1157635

Company Registration Number

08180701 (England and Wales)

Accountants and Independent examiner

A Carroll Associates
Chartered Tax Advisers and Certified public Accountants
9 Limefield Road
Salford
M7 4LZ

Report of the Directors/Trustees

The Directors/Trustees have pleasure in presenting their Report and Financial Statements of the Company/Charity for the year ended 31 August 2021.

The financial statements have been prepared in accordance with the accounting policies set out in the accounts and comply with the charity's governing document, the Companies Act 2006 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities in preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK (FRS 102)".

Trustees and Directors

The trustees in office throughout the year were A Carroll FCPA CTA, P Bridge, D Bridge and M Lewis

They are all also directors for the purposes of company law.

All trustees give of their time freely and no trustee remuneration was paid in the year.

Reference and Administration

Reference and Administration details are shown in the schedule of members of the board and professional advisers on page 3 of the financial statements.

Structure, governance and management

Melanoma UK incorporating factor 50 is a charity constituted as a company limited by guarantee and as such, is governed by its memorandum and articles of association.

The Directors/Trustees are responsible for the governance of the organisation and are active in all operational aspects of strategic management. Major policy decisions are decided at full directors'/ trustees' meetings.

Charitable Objects

To provide patient support and assist in the awareness of the condition of malignant melanoma, To provide funds for vital research with regards to the development of drugs to prolong and preserve quality of life to educate and increase awareness of the dangers of melanoma.

Achievements

During the year, the charity received all of its income from voluntary donations.

During the year, the charity received donations totalling £265,268 (2020:£323,616) for the direct purpose of the charity as detailed in the ensuing pages, in accordance to the charity objects.

The charity had a net surplus of £42,470 (2020: £88,539) which was held as current assets at the year end for further use of the charity's objects and needs.

In setting objectives and reviewing the Charity's aims and plans, the Trustees have given careful consideration to the Charity Commission's general guidance on public benefit.

Report of the Directors/Trustees (continued)

Risk Management

The Trustees have identified and reviewed the major risks to which the charity is exposed. Both manual and automated checks are regularly invoked, particularly those relating to the investments and finance of the Charity. The Trustees are satisfied that these systems and procedures mitigate any perceived risks.

Going Concern

The accounts have been prepared on a going concern basis as the directors have been assured of the continuing support from the company/charity's creditors.

Reserves Policy

The trustees retain reserves of at least £1,000, in order to enable the charity to meet future needs which they feel to be appropriate.

Responsibilities of the Directors/Trustees

Company Law requires the directors to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity as at the Balance Sheet Date, and of its incoming resources, including income and expenditure for the financial year.

Financial statements

In preparing those financial statements, the Directors/Trustees should follow best practice and

- a. Select suitable accounting policies and apply them consistently.
- b. Make judgments and estimates that are reasonable and prudent.
- c. Follow applicable accounting standards and the Charities SORP, disclosing and explaining any departures in the financial statements.
- d. Prepare the financial statements on the going concern basis unless it is inappropriate to assume that the charity will continue in operation.

The Directors/Trustees are responsible for maintaining proper accounting records which disclose with reasonable accuracy at any time the financial position of the charity and to enable them as Directors/Trustees to ensure that the financial statements comply with the Company Law.

The Directors/Trustees are also responsible for safeguarding the charity's assets and hence for taking reasonable steps for the prevention and detection of fraud and other regularities.

Approved by The Directors/Trustees on 26 June 2022

Mr Adrian Carroll - Director and Trustee

Independent Examiner's Report to the Trustees

I report on the financial statements of Melanoma UK Incorporating Factor 50 for the year ended 31 August 2021.

Respective Responsibilities of Governors and Examiner

The charity's trustees are responsible for the preparation of the accounts. The charity's trustees consider that an audit is not required for this year under section 144 of the Charities Act 2011 (the Charities Act) and that an independent examination is needed.

It is my responsibility to:

- examine the accounts under section 145 of the Charities Act,
- to follow the procedures laid down in the general Directions given by the Charity Commission (under section 145(5)(b) of the Charities Act, and to state whether particular matters have come to my attention.

Basis of Independent Examiner's Report

My examination was carried out in accordance with general Directions given by the Charity Commission. An examination includes a review of the accounting records kept by the charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts, and seeking explanations from the trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit, and consequently no opinion is given as to whether the accounts present a 'true and fair' view and the report is limited to those matters set out in the statement below.

In connection with my examination, no matter has come to my attention;

1. which gives me reasonable cause to believe that in, any material respect, the requirements:
 - to keep accounting records in accordance with section 130 of the Charities Act; and
 - to prepare accounts which accord with the accounting records and comply with the accounting requirements of the Charities Acthave not been met; or
2. to which, in my opinion, attention should be drawn in order to enable a proper understanding of the accounts to be reached.

I Friend
I Friend Accountancy Services
117 Albert Avenue
Prestwich
M25 0HE

Date: 26 June 2022

MELANOMA UK INCORPORATING FACTOR 50

Page 7

COMPANY LIMITED BY GUARANTEE

COMPANY NUMBER 08180701

CHARITY NUMBER 1157635

YEAR ENDED 31 AUGUST 2021

Statement of Financial Activities

	<u>Notes</u>	<u>2021</u> <u>£</u>	<u>2020</u> <u>£</u>
Incoming Resources	8	265,268	324,107
<hr/>			
Gross Income		265,268	324,107
Overheads			
Support costs	9	221,183	233,953
Governance costs	11	1,615	1,615
		222,798	235,568
Net income for the year		42,470	88,539
<hr/>			
Fund balances at 31 August 2021.		42,470	88,539
<hr/>			
transferred to designated account		(42,470)	(88,539)
<hr/>			
		-	-
<hr/>			

COMPANY LIMITED BY GUARANTEE

COMPANY NUMBER 08180701

CHARITY NUMBER 1157635

YEAR ENDED 31 AUGUST 2021

Balance Sheet
At 31 August 2021

	<u>Notes</u>	<u>2021</u>		<u>2020</u>
Fixed Assets		<u>£</u>	<u>£</u>	<u>£</u>
Tangible assets		8,227		10,970
Current Assets				
Debtors		-	4,252	
Cash at Bank		<u>293,867</u>	<u>238,476</u>	
		293,867	242,728	
Creditors				
Amounts due within one year	6	<u>(163,600)</u>	<u>(115,204)</u>	
Net current assets		<u>130,267</u>		127,524
Net Assets		<u>138,494</u>		<u>138,494</u>
Accumulated Funds				
Unrestricted funds	7	<u>138,494</u>		<u>138,494</u>

In approving these financial statements as directors of the company we hereby confirm:

- a. that for the year stated above the company was entitled to the exemption conferred by Section 477 of the Companies Act 2006 ;
- b. that no notice has been deposited at the registered office of the company pursuant to Section 476 requesting that an audit be conducted for the year ended 31 August 2021; and
- c. that we acknowledge our responsibilities for:
 1. ensuring that the company keeps accounting records which comply with Section 386 ; and
 2. preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its profit or loss for the year then ended in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the provisions of the Companies Act relating to financial statements, so far as applicable to the company.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

Approved by the board and signed on behalf of them all.

Date: 26 June 2022

Mr Adrian Carroll - Director and Trustee

The notes on the attached pages form part of the accounts

Notes to the Accounts

1. Principal Accounting Policies

Basis of Accounting

The financial statements have been prepared in accordance with the charity's governing document, the Companies Act 2006 and "Accounting and reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and ROI (FRS 102)".

The Charity is a Public Benefit Entity as defined by FRS 102.

Cash Flow

The accounts do not include a cash flow statement because the charity as a small reporting entity is exempt from the requirement to prepare such a statement.

Donations and Fund Accounting

Donations and Grants received for the general and main purposes of the Charity are included as unrestricted funds in the Statement of Financial Activities when receivable.

Donations and Grants for activities restricted by the donors are taken to restricted funds if the wishes and conditions of the donor are legally binding on the Trustees.

Resources Expended

Resources expended are accounted for on an accruals basis.

Management and administration costs are those incurred in connection with administration of the charity and compliance with constitutional and statutory requirements.

The irrecoverable element of VAT is included with the item of expense to which it relates.

2. Taxation

The Charitable Company is exempt from taxation on its charitable activities.

3. Incoming Resources

The total turnover of the company for the year has been derived from its principal activity wholly undertaken in the UK.

4. Company limited by Guarantee

The charity is a company limited by guarantee and has no share capital. The liability of each member in the event of winding up is limited to £1.

5. Control

The company is incorporated for charitable purposes and has no controlling party.

Notes to the Accounts (continued)

	<u>2021</u>	<u>2020</u>
	<u>£</u>	<u>£</u>
6. Creditors Amounts due within one year		
designated funds	115,968	93,499
tax and social security	44,402	-
Accrued expenses	3,230	21,705
	<u>163,600</u>	<u>115,204</u>
	Total	
	Charitable funds	
	<u>£</u>	
7. Unrestricted funds		
At 01 September 2020	-	-
Net Surplus for the year	42,470	88,539
At 31 August 2021	<u>42,470</u>	<u>88,539</u>
transferred to designated funds account	(42,470)	(88,539)
	<u>-</u>	<u>-</u>

MELANOMA UK INCORPORATING FACTOR 50

Page 11

COMPANY LIMITED BY GUARANTEE

COMPANY NUMBER 08180701

CHARITY NUMBER 1157635

YEAR ENDED 31 AUGUST 2021

Notes to the Accounts (continued)

	<u>2021</u>	<u>2020</u>
	£	£
8. Incoming Resources		
Donations Received	265,268	323,616
interest received	-	491.00
	<u>265,268</u>	<u>324,107</u>
9. Support costs		
Wages and salaries	110,212	118,253
employers pension	4,671	4,701
Travel expenses	2,623	2,094
Rent and rates	7,363	4,663
Insurance	1,566	1,566
Bank Charges	5,865	6,075
Light and heat	2,001	2,002
General and office expenses	13,701	14,251
Consultancy fees	39,930	39,431
Depreciation	2,742	5,481
training	900.00	-
Sundry expenses	-	775
Advertising costs	19,922	22,598
Website and social media	7,100	9,000
legal fees	-	1,258
Telephone	2,587	1,805
	<u>221,183</u>	233,953
Governance Costs		
Accountancy/ Independent Examiner fees	1,615	1,615
	<u>222,798</u>	<u>235,568</u>
10. Accumulated Funds		
Net Surplus for the year	42,470	88,539
Balance brought forward	-	-
Balance carried forward	<u>42,470</u>	<u>88,539</u>

MELANOMA UK INCORPORATING FACTOR 50

COMPANY LIMITED BY GUARANTEE

COMPANY NUMBER 08180701

CHARITY NUMBER 1157635

YEAR ENDED 31 AUGUST 2021

MELANOMA UK INCORPORATING FACTOR 50

COMPANY LIMITED BY GUARANTEE

COMPANY NUMBER 08180701

CHARITY NUMBER 1157635

YEAR ENDED 31 AUGUST 2021

MELANOMA UK INCORPORATING FACTOR 50

COMPANY LIMITED BY GUARANTEE

COMPANY NUMBER 08180701

CHARITY NUMBER 1157635

YEAR ENDED 31 AUGUST 2021

! for further